Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.

# Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.  **Read the full article:** [CNBC](https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html) *This article was originally published by CNBC. MoneyWiseInc provides expert curation of the best financial content from trusted sources.*